5 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
Follow Cdc25C phosphatase (211-221): new trials by email Literature Review of Cdc25C phosphatase (211-221) trials Research Report on Cdc25C phosphatase (211-221)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer CBP501 (16), CBP501 (25), Cisplatin - Pancreatic Cancer Stage IV | Phase 2 | Completed | CanBas Co. Ltd. | 36 | 2021-12-18 | 2023-08-15 |
| CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors CBP501 - Advanced Solid Tumors | Phase 1 | Completed | CanBas Co. Ltd. | 47 | 2017-10-25 | 2021-03-10 |
| Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) CBP501 + Cisplatin + Pemetrexed, Cisplatin + Pemetrexed - Metastatic Non-squamous Non Small Cell Lung Cancer | Phase 2 | Completed | CanBas Co. Ltd. | 195 | 2009-04-01 | 2017-05-24 |
| Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding - Malignant Pleural Mesothelioma, Solid Tumors | Phase 1 / Phase 2 | Completed | CanBas Co. Ltd. | 69 | 2008-05-01 | 2021-07-20 |
| Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors CBP501 and Cisplatin - Cancer, Solid Tumors | Phase 1 | Completed | CanBas Co. Ltd. | 48 | 2006-11-01 | 2017-03-14 |
Lung Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Pleural Effusion (1)
CanBas Co. Ltd. (5)
United States (5)
Ernesto Wasserman, MD (1) · Geoffrey I Shapiro, MD (1) · Lee Krug (1) · Takumi Kawabe, MD, PhD (1)